Cathelicidin LL-37 Fragments
Overview
Cathelicidin LL-37 fragments are truncated sequences derived from the human antimicrobial peptide LL-37, which is a 37-amino acid cleavage product of the cathelicidin precursor hCAP18. These fragments retain antimicrobial, immunomodulatory, and wound healing properties while potentially offering improved stability or reduced cytotoxicity. Specific fragments have been designed to preserve angiogenic and chemotactic activities relevant to tissue repair.
Key Research Findings
In vitro studies have demonstrated that certain LL-37 fragments maintain broad-spectrum antimicrobial activity against bacteria and fungi. Preclinical wound models in rodents have shown acceleration of healing through enhanced re-epithelialization and modulation of inflammatory responses. Clinical development has been limited, with no approved therapeutic applications to date.
Topical, Subcutaneous injection
Research Phase
Interested in Cathelicidin LL-37 Fragments?
Find a verified provider experienced with Cathelicidin LL-37 Fragments protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Cathelicidin LL-37 Fragments ProviderRelated Peptides
BPC-157
Research PhaseA synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis and the expression of growth factors including VEGF, EGF, and NO-mediated pathways. It has demonstrated cytoprotective and wound-healing properties across multiple tissue types in preclinical models, including tendon, muscle, ligament, and gastrointestinal mucosa.
TB-500 (Thymosin Beta-4)
In Clinical TrialsThymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue repair. It promotes wound healing by upregulating cell-building proteins such as actin and laminin, facilitating cell migration to sites of injury. TB-500 also has anti-inflammatory properties mediated through NF-kB pathway modulation.
GHK-Cu
Research PhaseA naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. GHK-Cu activates tissue remodeling by stimulating collagen synthesis, glycosaminoglycan production, and angiogenesis while suppressing fibrinogen synthesis. It modulates the activity of matrix metalloproteinases and influences over 4,000 genes related to tissue repair.
DSIP (Delta Sleep-Inducing Peptide)
Research PhaseA naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood of rabbits during induced sleep. DSIP modulates sleep architecture by promoting delta wave (slow-wave) sleep through interactions with the GABAergic system and hypothalamic sleep centers. It also exhibits stress-protective, analgesic, and neuromodulatory properties.